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ABSTRACT
Introduction: This study investigated the
effects of recurrent urinary tract infections
(rUTI) and the impact of prophylaxis on rUTI
and patients’ quality of life (QoL).
Methods: Altogether, 575 patients affected by
rUTI were included in a 6-month observational
study. QoL was assessed using the Hospital
Anxiety and Depression (HAD) and the
Leicester scales. Statistical analyses were
performed using SAS Version 8.2 software
(SAS Institute Inc., Cary, NC, USA). The
significance level was set at 5%. Spearman
correlation was used to assess the degree of
correlation between infectious episodes and
HAD and Leicester scores. For each parameter,
the comparison between Day 0 and Day 180 was
performed using Wilcoxon signed-rank test for
quantitative data.
Results: In total, 61.9% of patients suffering
from rUTI exhibited some degree of depression
at baseline (Day 0). Alternative oral non-
antimicrobial prophylactic treatment for rUTI
[Escherichia coli lyophilized bacterial lysate (OM-
89)] was administered to 94.4% of patients (1
capsule a day for 90 days), followed by a
3-month treatment-free period. At the end of
the study (Day 180), the mean number of UTI
decreased by 59.3% (P B 0.0001), the total HAD
score decreased by 32.1% (P B 0.0001), and the
mean Leicester score decreased by 44.0%
(P B 0.0001) from baseline. There was a
correlation trend between the reduction in the
numbers of UTI at the end of the study
compared to the 6 months prior to study entry
and the reduction in the anxiety, depression,
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total HAD scores, activity, feeling, and total
Leicester scores registered from Day 0 to Day
180, suggesting a lessening of emotional
problems, and social and functional handicaps
with decreasing UTI incidence.
Conclusions: This study showed that rUTI had
a negative impact on patients’ QoL and that
effective alternative prophylaxis significantly
improved their QoL.
Keywords: Cystitis; Prophylaxis; Quality of life;
Urinary tract infection
INTRODUCTION
Acute lower urinary tract infections (UTIs) in
adults consist of episodes of acute cystitis. They
occur in otherwise healthy individuals, mostly
women, with no risk factors such as underlying
disease or urinary tract abnormalities [1]. It is
estimated that 1 in 2 women will have at least 1
episode of UTI in their lifetime, and UTIs are at
least 50 times more common in premenopausal
women than in men [2]. Furthermore, up to
20% of women with acute cystitis develop
recurrent uncomplicated UTIs (3 or more
episodes per year) [1]. Patients experience a
psychological burden because they live with the
anxiety of sudden acute episodes. In the United
States, UTIs are responsible for seven million
medical visits a year, including two million for
cystitis alone, with three million patients
treated with antibiotics. The total estimated
cost is $3.5 billion; in Europe, the estimated
cost is €1.5 billion [3, 4].
The standard symptoms of acute
uncomplicated UTIs (cystitis) include acute
dysuria, pollakiuria, pain and burning
associated with micturition, urgent need to
urinate, as well as suprapubic tenderness
without fever. Escherichia coli strains are the
most common uropathogens, found in 80% of
urine specimens from patients with lower acute
uncomplicated UTI (cystitis), followed by
Staphylococcus saprophyticus (5–15%), and
aerobic Gram-negative bacteria, such as
Klebsiella pneumoniae and Proteus mirabilis
(5–10%) [5]. Although pathogen identification
is essential for testing antimicrobial
susceptibility and selecting appropriate
therapy, it is not routinely performed. In the
European Association of Urology (EAU)
guidelines [1], pathogen identification is
recommended only in cases of pregnancy,
recurring UTI, or fever and flank pain (to
exclude acute pyelonephritis) [6].
Empirical courses of antibiotics are generally
effective in treating cystitis (single dosing or
courses of 3–7 days), and the recommended
antibiotics include fosfomycin, nitrofurantoin,
cephalosporins, and trimethoprim–
sulfamethoxazole (TMP–SMX) [7]. However,
bacterial re-colonization can lead to relapses or
re-infections due to bacterial reservoirs [8] or
drug resistance [9]. Alternative effective
approaches to managing recurrent
uncomplicated UTIs comprise risk factor
evaluation, patient counseling, behavioral
modification, and non-antimicrobial
prophylaxis. Several non-antimicrobial
prophylactic agents are recommended by the
current EAU guidelines including probiotics
and oral immunostimulation with bacterial
extracts of E. coli (OM-89) [1]. Oral
immunostimulation with OM-89 was given a
Grade B recommendation in the guidelines due
to its well-documented efficacy and good
tolerability profile (and was rated as having
the highest level of clinical evidence, 1a). The
advantage of non-antimicrobial prophylaxis is
that, as compared to antibiotics, it that does not
contribute to the growing problem of bacterial
antibiotic resistance. This is particularly
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relevant for the treatment of UTIs due to the
paucity of antibiotics effective against Gram-
negative bacteria. OM-89 has been shown to
enhance the immune defenses against recurrent
UTIs (rUTIs) [10], and is a valuable component
in UTI treatment. Several well-designed double-
blind placebo-controlled studies and two
published meta-analyses involving over 1,000
patients [11–15] have shown that, when
administered over a 3-month period, OM-89
decreased the risk of recurrence, and
significantly reduced the signs and symptoms
of UTI, as well as the need for antibiotics over a
period of 12 months. However, these studies
have not addressed the effects of rUTIs on
quality of life (QoL).
Despite the social and economic relevance,
to date, few publications have focused on the
impact of frequent UTIs on QoL. Treating
repeated acute infections alone is not enough
to improve the QoL of these patients.
Determining the patient QoL is a key element
in assessing treatment efficacy, a consideration
that is at times neglected by health care
professionals. The sudden, unforeseeable, and
distressing nature of painful UTI episodes often
causes patient anxiety. The resulting social
handicap is known to induce feelings of self-
devaluation or culpability, which can lead to
clinical symptoms of depression [16–20]. This
social handicap particularly affects
premenopausal working women who
constitute a significant proportion of the
population experiencing UTIs. Furthermore,
rUTIs can result in functional handicap,
particularly in elderly patients in whom
infectious episodes may provoke or aggravate
incontinence, leading to rapid deterioration of
general health or initiating confusion [21–24].
All of these issues may significantly impact
patient QoL.
Previous small-scale studies [18, 25] and
observations from clinical practice have
indicated that recurrent cystitis has a negative
impact on QoL. Consequently, this
observational pilot study aimed to substantiate
the notion that recurrent cystitis negatively
impacts QoL. To this end, the impact of rUTIs
on patient QoL was evaluated, and changes in
patient QoL during preventative treatment
(prescribed by the attending physician) were
sought for.
METHODS
Study Design and Population
This international, prospective, observational,
multi-center, epidemiological pilot study was
conducted during 2005–2006, in accordance
with the ethical standards of the responsible
committees on human experimentation
(institutional and national) and with the 1975
Declaration of Helsinki, as revised in 2000 and
2008. Due to limited evidence of the impact of
rUTIs on QoL, this study was designed to
evaluate whether rUTIs have a negative impact
on patient QoL. The study did not interfere with
usual patient management, no special
treatment or examination was stipulated, and
the physician’s prescribing freedom was
maintained. The study population consisted of
patients affected by lower rUTIs (defined as C3
infectious episodes over the previous
12 months) who were treated by urologists,
gynecologists, hospital doctors, or general
practitioners. Patients were male or female,
[18 years of age, suffering from lower rUTIs,
and with a planned preventative treatment.
Patients unable to understand or complete the
QoL questionnaires, unwilling to participate,
who had a deformity of the urinary tract,
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neurogenic bladder, or presenting with
symptoms of vaginitis were excluded from the
study.
Data were collected from 151 centers in
seven countries: Egypt, Germany, Lebanon,
Peru, Poland, Portugal, and Switzerland. To
ensure even geographical distribution and fair
representation of patients from different
geographical areas, physicians were asked to
recruit a maximum of five patients meeting the
eligibility criteria and willing to participate in
the study. Each patient was examined at
inclusion (Day 0) and 6 months later (Day 180).
This observational pilot study aimed to
substantiate the notion that recurrent cystitis
has a negative impact on QoL. The primary
endpoint of the study was the relationship
between the number of infectious episodes
and the Hospital Anxiety and Depression
(HAD) scale [26]. The secondary endpoint was
the relationship between the Leicester impact
scale [27] and the number of infectious
episodes.
Evaluation Methods
Assessments on Day 0 and Day 180
On Day 0 and Day 180, physicians recorded the
patient UTI history (date of first infection, date
of start of recurrent signs, frequency of
infectious episodes, triggering factors, and
treatments received), description of urinary
symptoms concerning the last infection,
description of pain (intensity, duration, and
moments of appearance), previous
microbiological data (date of last examination
and microbiological diagnosis), and number of
UTI episodes over the previous 6 months. To
assess the presence and level of emotional
problems, as well as the social and functional
handicap in relation to rUTIs, the physician
asked the patient to complete the HAD scale
and Leicester impact scale questionnaires.
Assessment Scales
QoL is an outcome that can only be assessed by
the subjects themselves, without reference to
any norm. This is a specific approach in which
the patients express their perception of the
situation and the satisfaction (or dissatisfaction)
they experience compared with their
expectations [28]. Therefore, QoL assessment
was made using two specific questionnaires: a
generic form on anxiety and depression
disorders (i.e., the HAD scale) [26] and a UTI-
specific questionnaire on the functional and
social handicaps associated with UTIs (i.e., the
Leicester impact scale) [27].
Assessment of Emotional Problems
Emotional problems experienced by patients
during the previous week were assessed using
the HAD scale, which provides a reliable
method of detecting the most common signs
of anxiety and depressive disorders [26]. The
questionnaire comprises 14 questions (7
evaluate anxiety and 7 evaluate depression).
Each reply has a value of 0–3, and the
assessment was made in a semi-quantitative
manner using an adverb or qualifying short
sentence to evaluate symptom intensity.
Therefore, the possible total score ranged from
0 to 42, with both anxiety and depression
subscales ranging from 0 to 21.
The HAD scores were divided into three
ranges to assess the presence of anxiety or
depression: 0–7 = normal, 8–10 = possibly
indicative of anxiety or depression, and
C11 = probable presence of anxiety or
depression. A score of at least 8 on either
anxiety or depression subscales indicated an
emotional disorder.
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Assessment of Social or Functional Handicap
Social or functional handicap was assessed using
the Leicester impact scale. This is a valid and
reliable, interviewer-administered QoL tool for
patients with urinary storage symptoms [27]. It
was used to determine the impact of urinary
problems on daily activities (part 1) and on mood
and behavior (part 2). Part 1 of the scale assessed
nine situations in which urinary infections are
likely to interfere with daily activities (activity
score), categorized as often, rarely, never, activity
stopped because of urinary problems, and activity
stopped for other reasons. Part 2 of the scale was
used to determine the impact of symptoms on
mood and behavior (feeling score), categorized as
often, rarely, or never. The Leicester impact scale
was divided into four ranges: 0–14, 15–20, 21–30,
and 31–42. A score of [14 indicated that the
patient had some degree of functional or social
handicap, a score of[20 was suggestive of a major
social or functional handicap, and scores [31
indicated major social and functional handicaps.
Statistical Analysis
Statistical analyses were performed using SAS
Version 8.2 software (SAS Institute Inc., Cary, NC,
USA). The significance level was set at 5%.
Spearman correlation was used, as appropriate, to
assess the degree of correlation between infectious
episodes and the HAD and Leicester scores. For
each parameter, the comparison between Day 0
and Day 180 was performed using Wilcoxon
signed-rank test for quantitative data.
RESULTS
Patient Disposition
A total of 699 patients from seven countries
were initially enrolled in the study. The mean
patient age was 46.3 years. Among study
participants, 12.3% were male and 87.7% were
female. Data of 43 patients from Portugal were
accidently lost, and of 656 remaining patients
81 patients (12.3%) were lost to follow-up.
Therefore, 575 patients (87.6%) completed the
6-month (Day 180) follow-up visit and were
included in the primary endpoint analysis
(‘analysis population’). All patients who
received OM-89 prophylaxis at the standard
posology of 90 consecutive days (about
3 months) were followed up for a period of
3 months after treatment discontinuation.
Baseline and Day 180 Results
The most frequently reported urinary
symptoms concerning the last infection were
recorded at Day 0 (baseline). These were: pain
and/or burning during micturition (93.7%),
pollakiuria (82.4%), and dysuria (80.1%).
Approximately, one-third (29.8%) of patients
reported asthenia. On Day 180, the population
of patients suffering from asthenia or dysuria
was reduced by approximately half, and there
was a reduction of over 30% in the number of
patients suffering from pollakiuria or pain/
burning during micturition (Fig. 1).
The Wilcoxon test (P B 0.0001) showed that
the mean number of urinary infections was 2.7
[standard deviation (SD) = 1.2] during the
6 months prior to study entry, measured on
Day 0, and 1.1 (SD = 1.1) during the 6-month
study period, measured on Day 180; this
represents a statistically significant decrease of
1.6 (SD = 1.6).
During the study, 5% of patients did not
receive any preventative treatment for UTI. Of
the remaining 95%, the vast majority (94.4%)
were given OM-89 (1 capsule a day for 90 days),
followed by a 3-month treatment-free period.
Among the analysis population, 53.7% of
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patients were treated for acute UTI episodes:
41.6% of them received antibiotics, while the
remaining 12.1% received unspecified other
treatments.
At baseline, the HAD score revealed that 177
(32%), 153 (27.7%), and 12 (2.2%) patients
exhibited mild, moderate, and severe levels of
depression, respectively. The mean HAD
anxiety subscale score was 10.3 (SD = 4.1,
range 0–21), and the mean HAD depression
subscale score was 6.4 (SD = 3.6, range 0–18). In
total, 342 patients (61.8%) had at least minor
emotional disorders, 165 (29.9%) of whom
presented with a high anxious-depressive state.
At Day 180, the proportion of patients with
possibly clinically relevant anxiety/depression
levels (mild to severe anxiety or depression)
decreased. The difference was more significant
for the anxiety score, with a total reduction of
38.5% from Day 0 to Day 180 (Table 1). The
total HAD score at Day 180 indicated a 30.9%
increase in patients with a normal score (below
14), and a total decrease of 31% in patients
experiencing mild to severe anxiety or
depression (total HAD scores between 15 and
42; Fig. 2). At Day 180, the mean HAD anxiety
subscale score was 6.6 (SD = 3.7), the mean
HAD depression score was 4.8 (SD = 3.5), and
the total HAD score was 11.4 (SD = 6.5),
representing a statistically significant decrease
in total HAD score of 32.1% from baseline
(P B 0.0001). The mean number of urinary
episodes was 2.7 (SD = 1.2) on Day 0, and 1.1
(SD = 1.1) on Day 180, showing a statistically
significant decrease of 59.3% from baseline
(P B 0.0001). Thus, there was a correlation
trend between the reduction in the numbers
of UTIs from Day 0 to Day 180 and the
reduction in the anxiety, depression, and total
HAD scores, suggesting a lessening of emotional








































Fig. 1 Symptoms of urinary infection from the last urinary tract infection episode registered at Day 0 and Day 180—
analysis population (N = 575)
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The mean activity score was 10.4 (SD = 4.7)
on Day 0, and 4.0 (SD = 5.6) on Day 180,
showing a statistically significant 32.7%
decrease from baseline (P B 0.0001). The mean
feeling score was 9.1 (SD = 5.0) on Day 0, and
4.1 (SD = 4.2) on Day 180, which corresponds
to a statistically significant decrease of 54.9%
from baseline (P B 0.0001). The mean Leicester
score decreased from 19.3 (SD = 8.1) on Day 0
to 10.8 (SD = 7.9) on Day 180, representing a
statistically significant decrease of 44.0%
compared with baseline (P B 0.0001). The
mean number of urinary episodes was 2.7
(SD = 1.2) on Day 0, and 1.1 (SD = 1.1) on
Day 180, showing a statistically significant
decrease of 59.3% from baseline (P B 0.0001).
There was a correlation trend between the
reduction in number of UTIs from Day 0 to
Table 1 HAD depression and anxiety scores at Day 0 and Day 180 (N = 575)
Range Depression score, % of patients Anxiety score, % of patients
Day 0 Day 180 Day 0 Day 180
0–7 (normal) 64.4 77.2 26.7 65.2
8–10 (mild) 22.7 15.4 28.2 19.3
11–15 (moderate) 12.2 7.1 31.2 13.9
16–21 (severe) 0.7 0.4 13.9 1.6





























Fig. 2 Total HAD score at Day 0 and Day 180—analysis
population (N = 575, some data is missing). The HAD
questionnaire comprises 14 questions (7 evaluate anxiety
and 7 evaluate depression). Each reply has a value of 0–3,
giving a possible total score ranging from 0 to 42. Higher
scores indicate higher levels of anxiety and depression.
HAD hospital anxiety and depression
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Day 180 and the reduction in the activity,
feeling, and total Leicester scores. These
statistically significant reductions suggest a
lessening of social and functional handicap
with decreasing UTI incidence (Fig. 4).
Physicians reported overall improvement as
‘much better’ or ‘very much better’ in the vast
majority (82.4%) of patients. Furthermore,
12.7% of patients reported a ‘slightly better’
feeling, and only 3.9% reported ‘unchanged’
feeling. The remaining 1% of patients did not
report on their improvement.
DISCUSSION
Recurrent UTIs are a significant problem for
many patients. Health professionals do not
always appreciate the impact of this ostensibly
minor condition on a patient’s sense of well-
being; successful medical treatment of each
infection does not always translate into an
improvement in QoL [29].
This study evaluated the impact of rUTIs on
patient QoL before and during preventative
treatment, and while receiving the best
standard of care (i.e., during acute infection
episodes). The study did not interfere with usual
patient management, no special treatment or
examination was stipulated, and the physician’s
prescribing freedom was maintained. QoL is a
subjective, unempirical concept that does not
have a universally accepted definition. The
study used clinically validated questionnaires
(HAD and Leicester scales) to assess the presence
of anxiety or depression, and social or
functional handicap in patients who
experienced rUTIs. The questionnaires were




















Fig. 3 Evolution of HAD subscales and global score, and
number of urinary infection episodes between Day 0 and
Day 180—analysis population (N = 575). The HAD
subscales (anxiety score and depression score) were divided
into three ranges to assess the presence of anxiety or
depression: 0–7 normal, 8–10 possibly indicative of anxiety
or depression, and C11 probable presence of anxiety or
depression. A score of at least 8 on either the anxiety
subscale or depression subscale indicated an emotional
disorder. Asterisk the percentage reduction from Day 0. All
statistically signiﬁcant (P B 0.0001). HAD hospital anxiety
and depression
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the HAD and Leicester scales indicated an
improvement in QoL, which was supported by
the physicians’ assessment of overall
improvement as ‘very much better’ or ‘much
better’ in 82.4% of the study patients. The
comparison between the mean HAD score and
the mean number of UTIs showed a statistically
significant reduction in the mean number of
UTIs and a correspondingly statistically
significant reduction in the overall HAD score,
suggestive of an improvement in patient QoL.
This was similarly revealed by a comparison
between the mean Leicester score and the mean
number of UTIs, reinforcing the previously
described study outcomes.
Most physicians selected immunoactive
E. coli extract to prevent cystitis (94.4% of
the study population were treated with
immunoactive non-antimicrobial
prophylaxis, OM-89), rather than prophylaxis
with antibiotics. Interestingly, this choice of
prophylaxis anticipated future EAU guidelines
[1]. The immunoactive E. coli extract was first
mentioned in the 2008 EAU guidelines, and
was later recommended in the 2010 update
[1]. In the same update, a long-term, double-
blind, placebo-controlled study [13] was
referred to, which evaluated 453 patients
who received either immunotherapeutic
E. coli (OM-89) or matching placebo. The
results showed a highly significant reduction
(34%, P = 0.001) in UTI recurrences in the
active treatment group compared with
placebo. The current EAU guidelines [7]
recommend using antimicrobial prophylaxis
only when non-antimicrobial alternatives
have failed. Among the available strategies,
OM-89 is the most studied and has the






















Fig. 4 Reduction of Leicester scores and number of UTIs
between Day 0 and Day 180—Analysis population
(N = 575). The Leicester impact scale was divided into
four categories: 0–14, 15–20, 21–30, and 31–42. A score of
[14 indicated that the patient had some degree of
functional or social handicap, a score of[20 was suggestive
of a major social or functional handicap, and a score[31
indicated major social and functional handicaps. Asterisk
the percentage reduction from Day 0. All statistically
signiﬁcant (P B 0.0001). UTI urinary tract infection
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The study’s limitations are its open design
and lack of control group, which introduces
bias due to unblinded self-assessment. Despite
its observational design, this study was a unique
evaluation of the impact of rUTIs on patient
QoL due to its large sample size and
international multi-center design. As
highlighted by Bermingham and Ashe [30],
there is a paucity of data on the impact of
rUTIs on QoL in the literature. This study has
clearly highlighted the fact that rUTIs have a
negative impact on patient QoL, shown by the
prevalence of anxious-depressive symptoms and
socio-functional limitations in the study
population, which is consistent with results
reported previously in smaller populations [18,
25]. A clear improvement in QoL provided by
effective prophylaxis, such as OM-89, has been
revealed by this investigation.
In conclusion, this study highlights the need
for further randomized double-blind controlled
trials to confirm that non-antimicrobial
prophylaxis (OM-89) improves rUTI
management and patient QoL.
CONCLUSION
Our results showed that rUTI had a negative
impact on patients’ QoL and that effective
alternative prophylaxis significantly improved
their QoL.
ACKNOWLEDGMENTS
We would like to thank the patients and
researchers who participated in the study. This
research and the associated article processing
charges were supported by OM Pharma/Vifor
Pharma (Geneva, Switzerland), a company of
the Galenica group. All named authors meet the
ICMJE criteria for authorship for this
manuscript, take responsibility for the
integrity of the work as a whole, and have
given final approval for the version to be
published.
Conflict of interest. Stefania Ballarini is OM
Pharma/Vifor Pharma’ employee.
T. Mascarenhas, M. Zahran, E. Quimper, J.
Choucair and C. Iselin were investigators in
this study sponsored by OM Pharma/Vifor
Pharma. Julien Renard has no conflicts of
interest to declare.
Compliance with ethics guidelines. All the
study procedures conformed with the ethical
standards of the responsible committees on
human experimentation (institutional and
national) and with the 1975 Declaration of
Helsinki, as revised in 2000 and 2008. Springer’s
policy on Informed Consent has been followed.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. Grabe M, Bjerklund-Johansen TE, Botto H, et al.
European Association of Urology guidelines on
urological infections. 2010. http://www.uroweb.
org. Accessed April 1, 2010.
2. McCue JD. UTIs in at-risk patients: are they
‘complicated’? Infect Med. 1999;16:533–40.
3. Foxman B, Brown P. Epidemiology of urinary tract
infections: transmission and risk factors, incidence,
and costs. Infect Dis Clin North Am.
2003;17:227–41.
4. Foxman B. Epidemiology of urinary tract infections:
incidence, morbidity, and economic costs. Am J
Med. 2002;113:5S–13S.
134 Infect Dis Ther (2015) 4:125–135
5. Guay DR. Contemporary management of
uncomplicated urinary tract infections. Drugs.
2008;68:1169–205.
6. Gupta K, Hooton TM, Naber KG, et al. International
clinical practice guidelines for the treatment of
acute uncomplicated cystitis and pyelonephritis in
women: a 2010 update by the Infectious Diseases
Society of America and the European Society for
Microbiology and Infectious Diseases. Clin Infect
Dis. 2011;52:e103–20.
7. Grabe M, Bjerklund-Johansen TE, Botto H, et al.
European Association of Urology guidelines on
urological infections 2014 (limited update of 2013).
http://www.uroweb.org. Accessed April 1, 2014.
8. Mulvey MA, Schilling JD, Hultgren SJ.
Establishment of a persistent Escherichia coli
reservoir during the acute phase of a bladder
infection. Infect Immun. 2001;69:4572–9.
9. Epp A, Larochelle A, Lovatsis D, et al. Recurrent
urinary tract infection. J Obstet Gynaecol Can.
2010;32:1082–101.
10. Chiavaroli C, Moore A. An hypothesis to link the
opposing immunological effects induced by
bacterial lysate OM-89 in urinary tract infection
and rheumatoid arthritis. Biodrugs. 2006;20:141–9.
11. Schulman CC, Corbusier A, Michiels H, Taenzer HJ.
Oral immunotherapy of recurrent urinary tract
infections: a double-blind placebo-controlled
multicenter study. J Urol. 1993;150:917–21.
12. Magasi P, Panovics J, Illes A, Nagy M. Uro-Vaxom
and the management of recurrent urinary tract
infection in adults: a randomized multicenter
double-blind trial. Eur Urol. 1994;26:137–40.
13. Bauer HW, Alloussi S, Egger G, Blu¨mlein HM,
Cozma G, Schulman CC. A long-term,
multicenter, double-blind study of an Escherichia
coli extract (OM-89) in female patients with
recurrent urinary tract infections. Eur Urol.
2005;47:542–8.
14. Bauer HW, Rahlfs VW, Lauener PA, Blessmann GS.
Prevention of recurrent urinary tract infections
with immuno-active E. coli fractions: a meta-
analysis of five placebo-controlled double-blind
studies. Int J Antimicrob Agents. 2002;19:451–6.
15. Naber KG, Cho YH, Matsumoto T, Schaeffer AJ.
Immunoactive prophylaxis of recurrent urinary
tract infections: a meta-analysis. Int J Antimicrob
Agents. 2009;33:111–9.
16. Reid G, Bruce AW. Urogenital infections in women:
can probiotics help? Postgrad Med J.
2003;79:428–32.
17. Lowe NK, Ryan-Wenger NA. Military women’s risk
factors for and symptoms of genitourinary
infections during deployment. Mil Med.
2003;168:569–74.
18. Ellis AK, Verma S. Quality of life in women with
urinary tract infections: is benign disease a
misnomer? J Am Board Fam Pract. 2000;13:392–7.
19. De Moura JL. Urinary infection in the adult. Acta
Med Port. 1999;12:57–62.
20. Schleupner CJ. Urinary tract infections. Postgrad
Med. 1997;101:231–7.
21. Bula CJ, Ghilardi G, Wietlisbach V, Petignat C,
Francioli P. Infections and functional impairment
in nursing home residents: a reciprocal
relationship. J Am Geriatr Soc. 2004;52:700–6.
22. Van Oyen H, Van Oyen P. Urinary incontinence in
Belgium; prevalence, correlates and psychosocial
consequences. Acta Clin Belg. 2002;57:207–18.
23. Gonder MJ. Urologic considerations in the elderly.
Prim Care. 1982;9:71–5.
24. Woo BK, Daly JW, Allen EC, Jeste DV, Sewell DD.
Unrecognized medical disorders in older psychiatric
inpatients in a senior behavioral health unit in a
university hospital. J Geriatr Psychiatry Neurol.
2003;16:121–5.
25. Ernst EJ, Ernst ME, Hoehns JD, Bergus GR. Women’s
quality of life is decreased by acute cystitis and
antibiotic adverse effects associated with treatment.
Health Qual Life Outcomes. 2005;3:45.
26. Zigmond AS, Snaith RP. The hospital anxiety and
depression scale. Acta Psychiatr Scand.
1983;67:361–70.
27. Shaw C, Matthews RJ, Perry SI, et al. Validity and
reliability of a questionnaire to measure the impact
of lower urinary tract symptoms on quality of life:
the Leicester Impact Scale. Neurourol Urodyn.
2004;23:229–36.
28. Carr AJ, Gibson B, Robinson PG. Measuring quality
of life: Is quality of life determined by expectations
or experience? BMJ. 2001;322:1240–3.
29. Platt FW, Keating KN. Differences in physician and
patient perceptions of uncomplicated UTI
symptom severity: understanding the
communication gap. Int J Clin Pract.
2007;61:303–8.
30. Bermingham SL, Ashe JF. Systematic review of the
impact of urinary tract infections on health-related
quality of life. BJU Int. 2012;110:E830–6.
Infect Dis Ther (2015) 4:125–135 135
